Haemophilia

• 

  Publication Venue For

  • Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding..  24:63-69. 2018
  • A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease..  22:e562-e564. 2016
  • State of the art: von Willebrand disease..  22 Suppl 5:54-59. 2016
  • Von Willebrand factor for menorrhagia: a survey and literature review..  22:397-402. 2016
  • Coated platelet assay: a feasible approach to a complicated science..  22:e67-e70. 2016
  • Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?.  22:148-151. 2016
  • Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis..  21:81-87. 2015
  • Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials..  21:34-40. 2015
  • Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada..  20:e296-e303. 2014
  • Progressive improvement in wound healing with increased therapy in haemophilia B mice..  19:926-932. 2013
  • Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A..  19:595-601. 2013
  • Successful prophylactic regimens for transvaginal oocyte retrieval in women with bleeding diatheses..  19:e189-e191. 2013
  • Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond..  18 Suppl 4:112-119. 2012
  • The clotting system - a major player in wound healing..  18 Suppl 5:11-16. 2012
  • Factor X deficiency and pregnancy: preconception counselling and therapeutic options..  18:e277-e285. 2012
  • Diagnosis and management of women with bleeding disorders--international guidelines and consensus from an international expert panel..  17 Suppl 1:3-5. 2011
  • Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres..  17 Suppl 1:6-13. 2011
  • Women and bleeding disorders..  16 Suppl 5:160-167. 2010
  • The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery..  16:420-424. 2010
  • Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa..  16:510-517. 2010
  • Wound healing in haemophilia--breaking the vicious cycle..  16 Suppl 3:13-18. 2010
  • Risk factors for inhibitor formation in haemophilia: a prevalent case-control study..  15:1074-1082. 2009
  • von Willebrand disease in the 21st century: current approaches and new challenges..  15:1154-1158. 2009
  • Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease..  15:918-925. 2009
  • Complications of hysterectomy in women with von Willebrand disease..  15:926-931. 2009
  • Celecoxib does not delay cutaneous wound healing in haemophilia B mice..  15:615-616. 2009
  • Animal models of bleeding and tissue repair..  14 Suppl 3:62-67. 2008
  • von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)..  14:171-232. 2008